Junevity to Present Breakthrough Research on siRNA Therapeutics at American Aging Association’s 2026 Annual Meeting

Key Takeaways

• First in‑vivo siRNA data restores global gene networks in diabetic mice.
• Lead candidate shows durable knockdown with no safety issues in primates.
• RESET Platform leverages >1 billion RNA‑seq points to find Parkinson’s targets.
• Catalyze Agreement with Lilly ExploR&D accelerates neurodegeneration program.
• Quarterly dosing schedule could cut treatment costs and improve adherence.

Pulse Analysis

The rise of siRNA therapeutics has long promised precise gene modulation, but translating that precision into systemic health benefits remained elusive. Junevity’s recent in‑vivo data bridges that gap by showing a single‑target siRNA can reset entire gene networks, a concept that could redefine treatment strategies for age‑related diseases. By targeting transcription factors that orchestrate cellular aging, the approach leverages the body’s own regulatory machinery, offering a potentially safer and more durable alternative to traditional small‑molecule drugs.

Junevity’s RESET Platform combines massive RNA‑seq datasets, genetic linkage analyses, and machine‑learning algorithms to pinpoint novel transcription‑factor targets. The platform’s first candidate demonstrated robust knockdown and metabolic improvement in diabetic mice, with no adverse findings in high‑dose toxicology studies across rats and non‑human primates. Such safety signals, coupled with a projected quarterly dosing regimen, suggest lower manufacturing costs and better patient adherence—key advantages in a market increasingly focused on value‑based care.

The strategic Catalyze Agreement with Eli Lilly’s ExploR&D unit underscores industry confidence in siRNA’s therapeutic potential, especially for neurodegeneration. By applying the RESET Platform to Parkinson’s disease, Junevity aims to expand its pipeline beyond cardiometabolism, positioning itself at the forefront of next‑generation biologics. If human trials confirm these early results, the company could catalyze a shift toward gene‑network‑centric drug development, attracting investment and accelerating competition in the burgeoning anti‑aging biotech sector.